Kura Oncology (KURA) Liabilities and Shareholders Equity (2010 - 2026)

Kura Oncology (KURA) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $652.6 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 12.26% year-over-year to $652.6 million in Q1 2026; TTM through Mar 2026 was $2.7 billion, a 9.0% increase from a year earlier, with the FY2025 full-year figure at $738.4 million, down 2.87% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $652.6 million, down from $738.4 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for KURA reached as high as $760.2 million in Q4 2024 and fell as low as $426.0 million in Q1 2023.
• Historically, Liabilities and Shareholders Equity has averaged $558.4 million across 5 years, with a median of $498.6 million in 2022.
• Across the five-year window, Liabilities and Shareholders Equity slipped 20.16% in 2022 and jumped 69.32% in 2024, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $456.3 million in 2022, then retreated by 1.62% to $448.9 million in 2023, then surged by 69.32% to $760.2 million in 2024, then decreased by 2.87% to $738.4 million in 2025, then retreated by 11.62% to $652.6 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $652.6 million in Q1 2026, $738.4 million in Q4 2025, and $649.4 million in Q3 2025.